BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:24:00 PM | Browse: 1763 | Download: 1977
Publication Name World Journal of Orthopedics
Manuscript ID 8580
Country United States
ISSN 2218-5836 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Rheumatology
Manuscript Type Topic Highlights
Article Title Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
Manuscript Source Invited Manuscript
All Author List Lisa M Lundquist, Sabrina W Cole and Martha L Sikes
Funding Agency and Grant Number
Corresponding Author Lisa M Lundquist, PharmD, BCPS, College of Health Professions, Mercer University, 3001 Mercer University Drive, Atlanta, GA 30341, United States. lundquist_lm@mercer.edu
Key Words Tofacitinib; Rheumatoid arthritis; Janus kinase inhibitor
Core Tip Tofacitinib, a Janus kinase inhibitor, is a targeted, synthetic, disease-modifying antirheumatic drug (DMARD) approved for the treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to methotrexate. In numerous phase 2 and 3 trials, tofacitinib has proven to be safe and effective as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
Publish Date 2014-08-20 20:37
Citation Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 2014; 5(4): 504-511
URL http://www.wjgnet.com/2218-5836/full/v5/i4/504.htm
DOI http://dx.doi.org/10.5312/wjo.v5.i4.504
Full Article (PDF) WJO-5-504.pdf
Full Article (Word) WJO-5-504.doc